ArticleRare tumors2016

Three Years Sustained Complete Remission Achieved in a Primary Refractory ALK-Positive Anaplastic T Large Cell Lymphoma Treated with Crizotinib.

Carolina Valeria Mahuad et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.